1.1Refrigerated aqueous micelle storage
The hydrated dispersion is filled into sealed single-dose vials and stored at 2–8 °C. The micelles retain their aqueous corona and are dispensed directly from the vial.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The hydrated dispersion is filled into sealed single-dose vials and stored at 2–8 °C. The micelles retain their aqueous corona and are dispensed directly from the vial.
A volatile cosolvent shifts the block copolymer from assembled micelles to dissolved chains before vacuum evaporation deposits a thin polymer film. Added water hydrates the hydrophilic blocks, and the hydrophobic blocks associate into fresh micelle cores.
Trehalose is mixed into the aqueous dispersion before freezing. Sublimation leaves an amorphous sugar matrix that limits micelle contact, and the matrix dissolves when water is added.
A poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) triblock copolymer dissolves in chilled water. Warming above its concentration-dependent micellization temperature decreases hydration of the central block and drives its assembly into micelle cores.
A tangential-flow ultrafiltration membrane retains the micelles while water and dissolved cosolvent pass into the permeate. Water enters the recirculating retentate at the permeate flow rate, maintaining the retentate volume as the cosolvent concentration falls.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Hydroxyl-terminated poly(ethylene glycol) block copolymer micelles serve as reference dispersions in laboratories that measure particle size by dynamic light scattering. The micelles form in an organic cosolvent and water mixture, undergo dialysis against water, and are freeze-dried in single-use vials without added excipients. Each vial is reconstituted to its original fill volume, and the measured mean hydrodynamic diameter and polydispersity are compared with the lot values recorded before drying.
A solvent-compatible tangential flow filtration module replaces the dialysis reservoir after micelle formation in the organic cosolvent and water mixture. The membrane retains the micelles while solvent and water pass into the permeate, and a feed pump adds water at the permeate flow rate to maintain the retentate volume. Once the residual cosolvent reaches the specified limit, the retentate is filled into vials and freeze-dried without added excipients.
After dialysis, the aqueous micelle dispersion is metered into flat-bottom vials with a 16 mm internal diameter at 0.20 to 0.40 mL per vial, giving a nominal liquid depth of 1 to 2 mm. The filled vials freeze on a shelf at −45 °C and undergo primary drying under vacuum with the product temperature below the measured collapse temperature. Each vial is reconstituted with water to its original fill volume for comparison of particle size and interfacial rheology with the predrying dispersion.
A vial filling line meters the dialyzed micelle dispersion into glass vials and inserts vented lyophilization stoppers partway into the vial necks. A transfer system loads the vials onto temperature-controlled shelves, where water vapor exits through the stopper vents during drying. At the end of the cycle, the shelves compress the stoppers into their seated positions inside the chamber, and a downstream capper applies crimp seals.
Metering pumps deliver a block copolymer solution and an aqueous stream to a static mixer at a fixed total flow rate. An automated sampler sends an aliquot to a dynamic light scattering cell after a fixed equilibration interval, and a controller adjusts the pump ratio within a recipe window established from postdialysis size measurements. A diverter valve routes the dispersion to the dialysis vessel when measured diameter and polydispersity fall within their set limits, and the dialyzed batch proceeds to freeze-drying without added excipients.
A freeze dryer fitted with a capacitance manometer and a thermal conductivity vacuum gauge monitors primary drying of the filled micelle vials. The controller compares the chamber pressure readings because the thermal conductivity gauge responds to the declining water vapor fraction while the capacitance manometer measures absolute pressure independently of gas composition. After the readings remain within a calibrated difference for a preset hold time, the controller briefly isolates the chamber and starts secondary drying only if the pressure rise stays below a recipe limit.
A hydroxyl-terminated poly(ethylene glycol) block forms the hydrated corona around a poly(lactide) core. Dynamic light scattering measures a mean hydrodynamic diameter of 60 nm in the original aqueous dispersion before drying.
The aggregation number sets the dimensionless poly(ethylene glycol) grafting density above 7. The crowded corona shields the hydrophobic cores as ice concentrates the micelles, preserving the core–corona structure through drying.
The aqueous micelle dispersion is the sole vial fill. Primary drying removes ice by sublimation under vacuum, and secondary drying removes residual water by desorption.
An acetone solution of the block copolymer is mixed with water to form micelles in the mixed solvent. A dialysis membrane retains the micelles while acetone diffuses into a water reservoir that is replaced to maintain the concentration gradient.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The hydrodynamic diameter of the micelles was 40 nm at higher loading levels as opposed to 20-30 nm with lower drug levels (up to about 20% w/w).A · US 2009/0036389 A1 · ¶ 102
Then, D-mannitol as a lyophilizing agent was added to and completely dissolved into the polymeric micelle solution, and the resultant mixture was filtered through a filter with a pore size of 200 nm, followed by lyophilization, thereby providing a powdery docetaxel-containing polymeric micellar nanoparticle composition.B · US 2011/0257253 A1 · ¶ 97
Other lyoprotectants, including but not limited to, sucrose and raffinose offer similar stabilization of micellar structure during the drying process.A · US 2009/0036389 A1 · ¶ 36
The ABC and passenger compound are first dissolved in a volatile organic solvent which is miscible with water and may form an azeotrope with water. Water is added to drive micellization, and after sufficient partitioning of passenger compound into ABC micelles, the azeotrope (or solvent) is removed through evaporation, desirably at reduced pressure to provide an aqueous solution of the loaded micelles.A · US 2009/0036389 A1 · ¶ 50
More particularly, according to the method for preparing a drug-containing polymeric micellar nanoparticle composition disclosed herein, a drug and a polymer are dissolved in a water miscible organic solvent, and then an aqueous solution is added thereto to form polymeric micelles in the mixed organic solvent/water.B · US 2011/0257253 A1 · ¶ 18
An empty cell means only that no passage was reproduced there.
Other targets of the present formulation technology include other hydrophobic compounds such as flavoring agents, pigments, agricultural chemicals, fungicides and insecticides.A · US 2009/0036389 A1 · ¶ 3
Such molecules have favorable in vitro capabilities, however due to characteristics such as poor aqueous solubility, toxicity, chemical instability, and limited cellular permeability, these compounds require formulation to be therapeutically effective (Davis, S.A · US 2009/0036389 A1 · ¶ 4
In fact, such systems are known to have excellent compatibility with body fluids and to improve the solubilization ability of a poorly water-soluble drug and the bioavailability of a drug.B · US 2011/0257253 A1 · ¶ 2
Moreover, the solvent evaporation process essentially includes an operation of exposing reagents to a high temperature for a long period of time, and thus it may cause such problems as decomposition of pharmaceutically active ingredients or degradation of pharmacological effects.B · US 2011/0257253 A1 · ¶ 7
patent.fyi, US 2026/0355111 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355111/, SHA-256 e457f4a187a074e88ac162a03861c5b9dedd6518445fa4bafd1604de55bdc25c